Next 10 |
Ionis to hold olezarsen Phase 3 data webcast PR Newswire Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif. , March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it wil...
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire – First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction ...
2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...
2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...
2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...
2024-03-13 12:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 08:00:58 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) shares rose in early trading on Wednesday after the company reported positive results from a mid-stage trial of its investigational drug to treat a type of fatty liver disease.... Read the full article on S...
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire Significant improvement in steatohepatitis with > 2 point improvement in NAS score without worsening fibr...
2024-03-06 16:16:26 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi Begins Genetic Treatment IPO Rollout Moderna-backed Metagenomi sees stock fall 31% after $94M IPO Metagenomi prices initial off...
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most part...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis to hold olezarsen Phase 3 data webcast PR Newswire Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif. , March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it wil...
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire – First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction ...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for meta...